本帖最后由 老马 于 2012-1-13 21:20 编辑 6 q' S8 d4 f1 m& ]3 C1 H I( Q
) W d3 a" t' t' M7 M爱必妥和阿瓦斯丁的比较9 A6 o! u5 c @* }( w- e! E- |
4 `+ n3 Q5 o) H" `: `http://cancergrace.org/lung/2008/08/30/bms099-os-neg/. h# x) a% \* Q
% |3 L$ s" _( ]& Y* ^
% A2 _2 Q& f, `) `
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) y+ V2 ?+ Q* c0 F0 N# x9 S( {% U
==================================================
. x* A- b3 P; W2 @: R" i9 q, S: u HOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 h- F. _, B. H& W( Z r/ I
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ T$ w% R" {' I3 O% _; c8 eResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 T* y0 ]( h* E$ m. y: @8 B
|